Skip to content

NeurogesX Inc

Delisted

CIK 1385830fmd_19ZV0ZCPSWC2M4DDG44AN4JXNEManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2012, 11 periods

Latest annual · FY2011

Millions
Total revenues
12
Gross profit
11
Operating income
(39)
Net income
(50)
Free cash flow
(45)

Latest quarter · Q3 FY2012

Millions
Total revenues
3
Gross profit
3
Operating income
(1)
Net income
(4)
Free cash flow
(4)
Open Financials

NeurogesX Inc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2011FY2010ChangeSource
Revenue$11.5 million$8.3 million+39.2%10-K 2012-03-28 · proof
Gross profit$10.8 million$7.7 million+40%10-K 2012-03-28 · proof
Operating income-$39.2 million-$39.8 million10-K 2012-03-28 · proof
Net income-$49.5 million-$44.5 million10-K 2012-03-28 · proof
Cash from operating activities-$45.1 million-$42.4 million10-K 2012-03-28 · proof
Free cash flow-$45.2 million-$42.8 million10-K 2012-03-28 · proof
Total assets$39.2 million$50.9 million-22.9%10-K 2012-03-28 · proof
Total liabilities$107.1 million$92.1 million+16.2%10-K 2012-03-28 · proof
Cash and cash equivalents$9.1 million$8.7 million+5.1%10-K 2012-03-28 · proof
Total debt$67.6 million10-Q 2012-08-10 · proof
What was NeurogesX Inc's revenue in fiscal 2011?
NeurogesX Inc reported revenue of $11.5 million for fiscal 2011 (the year ended Dec 31, 2011), against $8.3 million the year before (+39.2%). Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What was NeurogesX Inc's gross profit in fiscal 2011?
NeurogesX Inc reported gross profit of $10.8 million for fiscal 2011 (the year ended Dec 31, 2011), against $7.7 million the year before (+40%). Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What was NeurogesX Inc's operating income in fiscal 2011?
NeurogesX Inc reported operating income of -$39.2 million for fiscal 2011 (the year ended Dec 31, 2011), against -$39.8 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What was NeurogesX Inc's net income in fiscal 2011?
NeurogesX Inc reported net income of -$49.5 million for fiscal 2011 (the year ended Dec 31, 2011), against -$44.5 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What was NeurogesX Inc's cash from operating activities in fiscal 2011?
NeurogesX Inc reported cash from operating activities of -$45.1 million for fiscal 2011 (the year ended Dec 31, 2011), against -$42.4 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What was NeurogesX Inc's free cash flow in fiscal 2011?
NeurogesX Inc reported free cash flow of -$45.2 million for fiscal 2011 (the year ended Dec 31, 2011), against -$42.8 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What are NeurogesX Inc's total assets?
As of Dec 31, 2011, NeurogesX Inc reported total assets of $39.2 million, against $50.9 million a year earlier (-22.9%). Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What are NeurogesX Inc's total liabilities?
As of Dec 31, 2011, NeurogesX Inc reported total liabilities of $107.1 million, against $92.1 million a year earlier (+16.2%). Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What are NeurogesX Inc's cash and cash equivalents?
As of Dec 31, 2011, NeurogesX Inc reported cash and cash equivalents of $9.1 million, against $8.7 million a year earlier (+5.1%). Source: the 10-K filed with the SEC on Mar 28, 2012. SEC
What is NeurogesX Inc's total debt?
As of Dec 31, 2011, NeurogesX Inc reported total debt of $67.6 million. Source: the 10-Q filed with the SEC on Aug 10, 2012. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1385830&period_type=annual&limit=5"

Information only, not investment advice.